Myo-Inositol for PCOS: Dosage, Benefits, and What…

Among the many supplements marketed for PCOS, myo-inositol stands out: it has more than 40 randomized controlled trials behind it, consistent evidence across multiple outcomes (insulin resistance, androgens, menstrual regularity, fertility), and a safety profile that includes use in pregnancy. If you are navigating PCOS and have not yet taken a serious look at myo-inositol, this is where to start.

What inositol is

Inositol is often classified as part of the B-vitamin family, though technically it is a carbocyclic sugar—a naturally occurring polyol found in cell membranes and in high concentrations in the brain, kidneys, and reproductive organs. It is the structural basis of the phosphatidylinositol phospholipids that make up cell membranes and serve as key second messengers in cellular signaling.

There are nine naturally occurring stereoisomers (structural arrangements) of inositol. Two are biologically most relevant for PCOS:

Myo-inositol (MI): The most abundant form in the body and in dietary sources. The predominant form in blood, follicular fluid, and most tissues. Functions as a second messenger for insulin signaling—it is part of the intracellular pathway by which insulin produces its metabolic effects.

D-chiro-inositol (DCI): Less abundant systemically but concentrated in certain tissues, particularly the liver and muscles. Involved in glycogen synthesis and glucose storage. The body converts myo-inositol to D-chiro-inositol via an enzyme (epimerase) that is insulin-sensitive.

Inositol is synthesized by the body from glucose and is also obtained from food—particularly citrus fruits, beans, grains, and nuts. It was formerly classified as vitamin B8 before it became clear that the body can synthesize it.

PCOS and inositol deficiency: what goes wrong

Women with PCOS have lower concentrations of myo-inositol in their follicular fluid compared to women without PCOS. This finding has been replicated across multiple studies and is consistent across PCOS phenotypes, including those without classic insulin resistance.

The connection to insulin signaling is central. In PCOS, insulin receptor signaling is impaired—specifically, the signaling cascade that converts receptor activation into intracellular metabolic effects is dysfunctional. Myo-inositol is a required component of this cascade; it is incorporated into glycosylphosphatidylinositol (GPI) anchors and inositol phosphoglycan (IPG) mediators that carry the insulin signal inside cells.

When inositol signaling is impaired in ovarian theca cells, these cells overproduce androgens in response to LH stimulation. This is the direct biochemical link between insulin resistance and elevated testosterone in PCOS—and why restoring inositol signaling reduces androgen production.

There is also an inositol metabolism abnormality in PCOS: the epimerase enzyme that converts myo-inositol to D-chiro-inositol is hyperactivated in PCOS ovaries, causing local depletion of myo-inositol and excess D-chiro-inositol. Paradoxically, supplementing DCI alone can worsen ovarian function by pushing this conversion further. This is why the ratio of myo to D-chiro inositol—not just total inositol—matters.

Myo-inositol vs D-chiro-inositol: the 40:1 ratio

This is the most practically important point in inositol supplementation for PCOS.

The ratio of myo-inositol to D-chiro-inositol in the blood is approximately 40:1. In ovarian follicular fluid, the ratio is much higher—concentrated myo-inositol with very little DCI. Supplementing D-chiro-inositol alone at high doses paradoxically impairs ovarian function by disrupting this local ratio in ovarian tissue.

A landmark study by Pkhaladze et al. (2015) demonstrated this directly: women given DCI alone showed worsening follicular development, while women given the 40:1 MI:DCI combination showed improvement. Earlier research by Nestler et al. (1999) had shown DCI benefits for insulin resistance, but this was before the ovarian-specific ratio implications were understood.

The current consensus recommendation from Italian PCOS researchers (who have led much of this research) is the 40:1 ratio: approximately 40 parts myo-inositol to 1 part D-chiro-inositol. This is available commercially as Ovasitol (Theralogix) and under several European brands. A standard dosing packet of Ovasitol provides 2000mg myo-inositol + 50mg D-chiro-inositol.

For most women with PCOS, supplementing myo-inositol alone (without DCI) is a reasonable and evidence-backed approach—most trials showing benefit used myo-inositol alone. The 40:1 combination may provide additional benefit, particularly for fertility outcomes, but it is not mandatory.

Clinical evidence: what the trials actually show

The myo-inositol evidence base for PCOS is extensive enough to have supported multiple meta-analyses:

Insulin resistance: Multiple RCTs show myo-inositol reduces fasting insulin and HOMA-IR in women with PCOS. A 2017 meta-analysis by Unfer et al. found significant HOMA-IR reduction across 11 trials. In direct comparison trials, myo-inositol has performed comparably to metformin for insulin resistance outcomes, with meaningfully fewer GI side effects.

Androgens: Total testosterone and free androgen index (FAI) are consistently reduced in myo-inositol trials. A 2016 meta-analysis found statistically significant reductions in testosterone across pooled trial data. The mechanism—improved insulin signaling in theca cells reducing LH-stimulated androgen production—is well-characterized.

Menstrual regularity: Roughly 70-75% of women with PCOS show improved menstrual cycle regularity with myo-inositol supplementation in trials of 3-6 months. This is one of the most consistently reported outcomes and often noticed by women before hormonal lab values change.

Ovulation: Multiple trials measuring ovulation directly (via LH surge tracking or follicular monitoring) show myo-inositol significantly increases ovulation frequency in anovulatory PCOS.

Comparison to metformin: Several head-to-head trials have now compared myo-inositol to metformin. A pivotal 2017 RCT by Minozzi et al. compared 4g myo-inositol vs 1500mg metformin in 120 women over 6 months. Results showed comparable improvements in insulin resistance and androgen levels, with the myo-inositol group showing better ovulation outcomes and dramatically fewer GI side effects.

Fertility evidence: egg quality and IVF

The fertility applications of myo-inositol have some of the most striking evidence in this literature.

Follicular fluid inositol levels are correlated with egg quality. Multiple studies show that IVF patients with higher follicular fluid myo-inositol levels have better oocyte quality, higher fertilization rates, and higher embryo quality scores. Supplementing myo-inositol to increase follicular fluid concentrations is now a recognized strategy in reproductive medicine.

Key fertility findings:

Papaleo et al. (2007): Myo-inositol co-treatment during IVF significantly improved egg quality, reduced the number of days of ovarian stimulation needed, and reduced FSH required for stimulation.
Ciotta et al. (2011): MI improved pregnancy rates and reduced cycle cancellation in PCOS patients undergoing IVF.
Unfer et al. (2011): MI + folic acid improved both spontaneous and clomiphene-induced pregnancy rates in PCOS.

For women pursuing IVF or ovulation induction with clomiphene or letrozole, myo-inositol pre-treatment and co-treatment is supported by evidence and routinely used in European fertility clinics.

Dosage: how much to take

The dosage used in the majority of clinical trials is 4000mg (4g) of myo-inositol per day, typically divided into two doses of 2000mg.

Common trial formulations:

2000mg myo-inositol twice daily (morning and evening with meals)
Some trials used 4000mg as a single dose with evidence of effectiveness

The 40:1 MI:DCI combination (Ovasitol format): 2000mg MI + 50mg DCI twice daily.

For lower-dose applications (general antioxidant support, mild insulin resistance): some practitioners use 2000mg/day as a starting dose with plans to increase if response is insufficient.

There is a practical ceiling: doses above 4000mg/day do not appear to provide additional benefit and may paradoxically worsen some outcomes at very high doses (more DCI conversion becomes a concern).

How to take it

Myo-inositol is available in powder and capsule form. Powder is more economical for the gram-level doses needed and dissolves readily in water, juice, or smoothies. The taste is mild and slightly sweet—most people find it easily palatable in water.

Splitting the dose between morning and evening maintains steadier levels throughout the day and aligns with the way clinical trials typically administered it. Taking with meals is a practical approach and may slightly reduce the mild GI discomfort some people experience.

No specific foods are required alongside myo-inositol—it does not have the food-interaction complexity of zinc or berberine. It mixes simply into any beverage.

Timeline: what to expect and when

Realistic expectations based on the clinical literature:

Weeks 1-4: Some women report reduced bloating or improved energy. Limited hormonal changes at this early stage. Insulin signaling begins improving at the cellular level but is not yet reflected in lab values or cycle changes.

Month 1-3: Menstrual cycle changes are often the first meaningful sign of response—cycles that were 45-90+ days begin shortening toward a more regular pattern. Some women resume regular cycles by month 2-3. Acne may show modest improvement.

Month 3-6: Hormonal lab values (testosterone, LH/FSH ratio, insulin) show significant changes in women who respond. Ovulation frequency increases. Women tracking basal body temperature or using OPK tests often confirm ovulation in this window for the first time in months or years.

For fertility: Some ovulation improvement can appear as early as 1-3 months, but 3-6 months of pretreatment before attempting conception is commonly recommended to allow egg quality improvements to accumulate.

Combining with NAC and alpha-lipoic acid

Myo-inositol is often combined with other supplements targeting PCOS through complementary mechanisms.

NAC (N-acetyl cysteine): NAC addresses oxidative stress (via glutathione) and has some insulin sensitizing effects through separate pathways. The combination of myo-inositol + NAC has been studied. One studied combination: MI 4g + DCI 100mg + NAC 600mg daily. For detailed NAC evidence in PCOS, see NAC for PCOS.

Alpha-lipoic acid (ALA): ALA regenerates glutathione and also has insulin sensitizing properties. A formulation combining MI 1000mg + ALA 400mg + folic acid has been studied in IVF populations with favorable outcomes (Vitale et al., 2016).

Berberine: Complementary to inositol—berberine activates AMPK while inositol restores insulin second messenger signaling. The combination addresses insulin resistance from two distinct angles. Monitor blood sugar closely if combining, as additive effects can be significant.

Lean PCOS vs classic PCOS: does it matter?

Lean PCOS (PCOS in women with normal BMI and apparently normal insulin sensitivity on standard tests) deserves special consideration. Many conventional treatments are less effective in lean PCOS because the primary driver is often elevated LH rather than insulin resistance.

Even in lean PCOS, ovarian inositol depletion is documented—the follicular fluid inositol deficit exists regardless of BMI. And myo-inositol trials show benefits in lean PCOS populations, though the magnitude is somewhat smaller than in insulin-resistant PCOS.

For lean PCOS specifically, the inositol focus on improving follicular fluid quality may be more relevant than its insulin sensitizing effects. This makes myo-inositol a reasonable first-line supplement even for lean PCOS women who have been told their PCOS "isn't related to insulin."

Safety in early pregnancy

Myo-inositol is considered one of the safest supplements in the periconception period and early pregnancy. Several lines of evidence support continued use into early pregnancy for women with PCOS:

Myo-inositol combined with folic acid has been shown to reduce neural tube defect risk, potentially better than folic acid alone (though folic acid remains standard of care).
Some data suggests myo-inositol in early pregnancy reduces gestational diabetes risk in PCOS pregnancies, which are at higher baseline risk.
One Italian RCT showed reduced miscarriage rates in women with PCOS who continued myo-inositol into the first trimester.

Standard prenatal vitamins do not contain myo-inositol, so continuing supplementation separately (with your OB's awareness) is the approach used in European fertility and obstetrics practices where this supplementation is more mainstream.

The bottom line

Myo-inositol is the most evidence-backed supplement for PCOS. Four grams per day in two divided doses is the clinically established dose. The 40:1 myo-inositol to D-chiro-inositol ratio is the appropriate formulation if using a combination product. Expect menstrual cycle improvements in months 1-3 and hormonal changes in months 3-6. Fertility improvements, including egg quality and ovulation rate, are well-documented in IVF and ovulation induction contexts. It combines well with NAC for comprehensive PCOS management and is generally safe to continue into early pregnancy under medical supervision.

Track your supplement timing and results with Optimize. Start free.

Myo-Inositol for PCOS: Dosage, Benefits, and What to Expect